91 related articles for article (PubMed ID: 19783211)
21. The BioSTAR(r) device versus the CardioSEAL(r) device in patent foramen ovale closure: comparison of mid-term efficacy and safety.
Van den Branden BJ; Luermans JG; Post MC; Plokker HW; Ten Berg JM; Suttorp MJ
EuroIntervention; 2010 Sep; 6(4):498-504. PubMed ID: 20884438
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of patent foramen ovale closure with no-device left behind: first-in-man percutaneous suture closure.
Ruiz CE; Kipshidze N; Chiam PT; Gogorishvili I
Catheter Cardiovasc Interv; 2008 Jun; 71(7):921-6. PubMed ID: 18412251
[TBL] [Abstract][Full Text] [Related]
23. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke.
Thanopoulos BV; Dardas PD; Karanasios E; Mezilis N
Catheter Cardiovasc Interv; 2006 Nov; 68(5):741-6. PubMed ID: 17039525
[TBL] [Abstract][Full Text] [Related]
24. Biodisk: a new device for closure of patent foramen ovale: a feasibility study in swine.
Pavcnik D; Takulve K; Uchida BT; Pavcnik Arnol M; VanAlstine W; Keller F; Rösch J
Catheter Cardiovasc Interv; 2010 May; 75(6):861-7. PubMed ID: 20432391
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease.
Mansencal N; Mitry E; Pillière R; Lepère C; Gérardin B; Petit J; Gandjbakhch I; Rougier P; Dubourg O
Am J Cardiol; 2008 Apr; 101(7):1035-8. PubMed ID: 18359327
[TBL] [Abstract][Full Text] [Related]
26. ASD and PFO closure with the Solysafe septal occluder - results of a prospective multicenter pilot study.
Ewert P; Söderberg B; Dähnert I; Hess O; Schuler G; Bussmann C; Bernhard J; Sick P
Catheter Cardiovasc Interv; 2008 Feb; 71(3):398-402. PubMed ID: 18288739
[TBL] [Abstract][Full Text] [Related]
27. Transcatheter closure of patent foramen ovale without an implant: initial clinical experience.
Sievert H; Fischer E; Heinisch C; Majunke N; Roemer A; Wunderlich N
Circulation; 2007 Oct; 116(15):1701-6. PubMed ID: 17893276
[TBL] [Abstract][Full Text] [Related]
28. Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder.
Spies C; Strasheim R; Timmermanns I; Schraeder R
Eur Heart J; 2006 Feb; 27(3):365-71. PubMed ID: 16254007
[TBL] [Abstract][Full Text] [Related]
29. Comparison of contemporary devices used for transcatheter patent foramen ovale closure.
Spies C; Reissmann U; Timmermanns I; Schräder R
J Invasive Cardiol; 2008 Sep; 20(9):442-7. PubMed ID: 18762672
[TBL] [Abstract][Full Text] [Related]
30. Transcatheter intracardiac echocardiography-assisted closure of interatrial shunts: complications and midterm follow-up.
Rigatelli G; Cardaioli P; Giordan M; Dell'Avvocata F; Braggion G; Piergentili C; Roncon L; Faggian G
Echocardiography; 2009 Feb; 26(2):196-202. PubMed ID: 19207996
[TBL] [Abstract][Full Text] [Related]
31. Early post-procedural migraine attack predicts migraine resolution after patent foramen ovale transcatheter closure.
Rigatelli G; Cardaioli P; Dell'Avvocata F; Braggion G; Giordan M; Chinaglia M
Minerva Cardioangiol; 2008 Oct; 56(5):461-5. PubMed ID: 18813181
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of transcatheter patent foramen ovale closure in migraineurs with moderate to large right-to-left shunt and instrumental evidence of cerebrovascular damage.
Papa M; Gaspardone A; Fragasso G; Ajello S; Gioffrè G; Iamele M; Iani C; Margonato A
Am J Cardiol; 2009 Aug; 104(3):434-9. PubMed ID: 19616680
[TBL] [Abstract][Full Text] [Related]
33. Transcatheter patent foramen ovale closure for secondary prevention of paradoxical embolic events: acute results from the FORECAST registry.
Alameddine F; Block PC
Catheter Cardiovasc Interv; 2004 Aug; 62(4):512-6. PubMed ID: 15274163
[TBL] [Abstract][Full Text] [Related]
34. Interatrial shunt closure devices in patients with nickel allergy.
Reddy BT; Patel JB; Powell DL; Michaels AD
Catheter Cardiovasc Interv; 2009 Oct; 74(4):647-51. PubMed ID: 19777603
[TBL] [Abstract][Full Text] [Related]
35. Resolution of migraine by transcatheter patent foramen ovale closure with Premere Occlusion System in a preliminary series of patients with previous cerebral ischemia.
Rigatelli G; Cardaioli P; Braggion G; Giordan M; Fabio D; Aggio S; Roncon L; Chinaglia M
Catheter Cardiovasc Interv; 2007 Sep; 70(3):429-33. PubMed ID: 17722021
[TBL] [Abstract][Full Text] [Related]
36. Late presentation of CardioSEAL PFO closure device fracture and thrombus formation three years after device implantation.
Narayan V; Puri P; Mehra AO
J Invasive Cardiol; 2008 Aug; 20(8):E247-9. PubMed ID: 18688073
[TBL] [Abstract][Full Text] [Related]
37. Atrial fibrillation following device closure of patent foramen ovale.
Burow A; Schwerzmann M; Wallmann D; Tanner H; Sakata T; Windecker S; Meier B; Delacrétaz E
Cardiology; 2008; 111(1):47-50. PubMed ID: 18239392
[TBL] [Abstract][Full Text] [Related]
38. [Feasibility and results of transcatheter treatment of patent foramen ovale associated with atrial septal aneurysm. Experience of a general hospital in Mulhouse, France].
Roth O; Jacquemin L; Kenizou D; Mettauer B; Monassier JP
Ann Cardiol Angeiol (Paris); 2007 Nov; 56(5):201-7. PubMed ID: 17931590
[TBL] [Abstract][Full Text] [Related]
39. Sustained long-term benefit of patent foramen ovale closure on migraine.
Trabattoni D; Fabbiocchi F; Montorsi P; Galli S; Teruzzi G; Grancini L; Gatto P; Bartorelli AL
Catheter Cardiovasc Interv; 2011 Mar; 77(4):570-4. PubMed ID: 21351231
[TBL] [Abstract][Full Text] [Related]
40. Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm scheduled for transcatheter closure may play a role in aura genesis.
Rigatelli G; Dell'avvocata F; Cardaioli P; Ronco F; Giordan M; Braggion G; Aggio S; Chinaglia M; Cheng JP; Nanjundappa A
J Interv Cardiol; 2010 Aug; 23(4):370-6. PubMed ID: 20624202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
